Chronic urticaria in the real-life clinical practice setting in the UK: results from the noninterventional multicentre AWARE study.
Activities of Daily Living
/ psychology
Adult
Angioedema
/ etiology
Anti-Allergic Agents
/ administration & dosage
Body Mass Index
Chronic Urticaria
/ diagnosis
Comorbidity
Cost of Illness
Cyclosporine
/ administration & dosage
Efficiency
Female
Health Resources
/ statistics & numerical data
Histamine H1 Antagonists
/ therapeutic use
Humans
Immunosuppressive Agents
/ administration & dosage
Male
Middle Aged
Omalizumab
/ administration & dosage
Patient Reported Outcome Measures
Prospective Studies
Quality of Life
/ psychology
Severity of Illness Index
United Kingdom
/ epidemiology
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
19
12
2019
revised:
20
03
2020
accepted:
25
03
2020
pubmed:
5
4
2020
medline:
29
7
2021
entrez:
5
4
2020
Statut:
ppublish
Résumé
Chronic urticaria (CU) is a skin condition characterized by repeated occurrence of itchy weals and/or angio-oedema for > 6 weeks. To provide data demonstrating the real-life burden of CU in the UK. This UK subset of the worldwide, prospective, noninterventional AWARE study included patients aged 18-75 years diagnosed with H1-antihistamine (H1-AH)-refractory chronic spontaneous urticaria (CSU) for > 2 months. Baseline characteristics, disease activity, treatments, comorbidities and healthcare resource use were documented. Quality of life (QoL), work productivity and activity impairment were assessed. Baseline analysis included 252 UK patients. Mean age and body mass index were 45.0 years and 29.0 kg/m Adult H1-AH-refractory patients with CU in the UK reported high rates of healthcare resource use and impairment in QoL, work productivity and activity at baseline. The differing structures of UK healthcare may explain the high study discontinuation rates versus other countries.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic urticaria (CU) is a skin condition characterized by repeated occurrence of itchy weals and/or angio-oedema for > 6 weeks.
AIM
OBJECTIVE
To provide data demonstrating the real-life burden of CU in the UK.
METHODS
METHODS
This UK subset of the worldwide, prospective, noninterventional AWARE study included patients aged 18-75 years diagnosed with H1-antihistamine (H1-AH)-refractory chronic spontaneous urticaria (CSU) for > 2 months. Baseline characteristics, disease activity, treatments, comorbidities and healthcare resource use were documented. Quality of life (QoL), work productivity and activity impairment were assessed.
RESULTS
RESULTS
Baseline analysis included 252 UK patients. Mean age and body mass index were 45.0 years and 29.0 kg/m
CONCLUSIONS
CONCLUSIONS
Adult H1-AH-refractory patients with CU in the UK reported high rates of healthcare resource use and impairment in QoL, work productivity and activity at baseline. The differing structures of UK healthcare may explain the high study discontinuation rates versus other countries.
Substances chimiques
Anti-Allergic Agents
0
Histamine H1 Antagonists
0
Immunosuppressive Agents
0
Omalizumab
2P471X1Z11
Cyclosporine
83HN0GTJ6D
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1010Subventions
Organisme : Novartis Pharmaceuticals UK Limited
Informations de copyright
© 2020 The Authors. Clinical and Experimental Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Zuberbier T, Aberer W, Asero R et al. The EAACI/GA2LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy 2017; 2018(): 1393-414.
Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy 2011; 66: 317-30.
Sánchez-Borges M, Asero R, Ansotegui IJ et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J 2012; 5: 125-47.
Maurer M, Abuzakouk M, Bérard F et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy 2017; 72: 2005-16.
Maurer M, Houghton K, Costa C et al. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J 2018; 11: 32.
Koti I, Weller K, Makris M et al. Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria. Dermatology 2013; 226: 371-9.
Maurer M, Raap U, Staubach P et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy 2019; 49: 655-62.
Thomsen SF, Pritzier EC, Anderson CD et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol 2017; 31: 1048-55.
Maurer M, Staubach P, Raap U et al. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study. Clin Exp Allergy 2017; 47: 684-92.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-16.
Młynek A, Zalewska-Janowska A, Martus P et al. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63: 777-80.
Balestroni G, Bertolotti G. [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis 2012; 78: 155-9.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
Costa AC, Rosmaninho I, Guilherme A et al. Chronic urticaria in the real-life clinical practice setting in Portugal: baseline results from the non-interventional multicentre AWARE study. Acta Med Port 2019; 32: 133-40.
Lapi F, Cassano N, Pegoraro V et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. Br J Dermatol 2016; 174: 996-1004.
Mendelson MH, Bernstein JA, Gabriel S et al. Patient-reported impact of chronic urticaria compared with psoriasis in the United States. J Dermatolog Treat 2017; 28: 229-36.
O'Donnell BF, Lawlor F, Simpson J et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197-201.
Vietri J, Tian H, Gabriel S et al. Economic burden of chronic spontaneous urticaria and psoriasis: patients perspective from Europe. Value Health 2015; 18: A424-5.
Shalom G, Magen E, Babaev M et al. Chronic urticaria and the metabolic syndrome: a cross-sectional community-based study of 11 261 patients. J Eur Acad Dermatol Venereol 2018; 32: 276-81.
Soria A, Du-Thanh A, Amsler E et al. Obesity is not associated with severe chronic urticaria in a French cohort. J Eur Acad Dermatol Venereol 2018; 32: e247-9.